Target detection in clutter for sonar imagery

This thesis is concerned with the analysis of side-looking sonar images, and specif- ically with the identification of the types of seabed that are present in such images, and with the detection of man-made objects in such images. Side-looking sonar images are, broadly speaking, the result of the physical interaction between acous- tic waves and the bottom of the sea. Because of this interaction, the types of seabed appear as textured areas in side-looking sonar images. The texture descrip- tors commonly used in the field of sonar imagery fail at accurately identifying the types of seabed because the types of seabed, hence the textures, are extremely variable. In this thesis, we did not use the traditional texture descriptors to identify the types of seabed. We rather used scattering operators which recently appeared in the field of signal and image processing. We assessed how well the types of seabed are identified through two inference algorithms, one based on affine spaces, and the other based on the concept of similarity by composition. This thesis is also concerned with the detection of man-made objects in side-looking sonar im- ages. An object detector may be described as a method which, when applied to a certain number of sonar images, produces a set of detections. Some of these are true positives, and correspond to real objects. Others are false positives, and do not correspond to real objects. The present object detectors suffer from a high false positive rate in complex environments, that is to say, complex types of seabed. The hypothesis we will follow is that it is possible to reduce the number of false positives through a characterisation of the similarity between the detections and the seabed, the false positives being by nature part of the seabed. We will use scattering operators to represent the detections and the same two inference algorithms to quantify how similar the detections are to the seabed

At-Risk Phenotype of Neurofibromatose-1 Patients: A Multicentre Case-Control Study

<p>Abstract</p> <p>Objectives</p> <p>To assess associations between subcutaneous neurofibromas (SC-NFs) and internal neurofibromas in patients with neurofibromatosis type 1 (NF-1) and to determine whether the association between SC-NFs and peripheral neuropathy was ascribable to internal neurofibromas.</p> <p>Patients and methods</p> <p>Prospective multicentre case-control study. Between 2005 and 2008, 110 NF-1 adults having two or more SC-NFs were individually matched for age, sex and hospital with 110 controls who had no SC-NF. Patients underwent standardized MRI of the spinal cord, nerve roots and sciatic nerves and an electrophysiological study. Analyses used adjusted multinomial logistic regression (ORa) to estimate the risk of the presence of internal neurofibromas or peripheral neuropathies associated with patients presented 2 to 9 SC-NFs, at least 10 SC-NFs as compared to patients without any (referential category).</p> <p>Results</p> <p>Cases had a mean age of 41 (± 13) years; 85 (80%) had two to nine SC-NFs and 21 (19%) at least ten SC-NFs. SC-NFs were more strongly associated with internal neurofibromas in patients with ten or more SC-NFs than in patients with fewer NF-SCs (e.g., sciatic nerve, aOR = 29.1 [8.5 to 100] vs. 4.3 [2.1 to 9.0]). The association with SC-NFs was stronger for diffuse, intradural, and > 3 cm internal neurofibromas than with other internal neurofibromas. Axonal neuropathy with slowed conduction velocities (SCV) was more strongly associated with having at least ten SC-NFs (aOR = 29.9, 5.5 to 162.3) than with having fewer SC-NFs (aOR = 4.4, 0.9 to 22.0). Bivariate analyses showed that the association between axonal neuropathy with SCV and sciatic neurofibromas was mediated by the association between SC-NFs and sciatic neurofibromas.</p> <p>Conclusion</p> <p>The at-risk phenotype of NF-1 patients (i.e. NF-1 patients with SC-NFs) is ascribable to associations linking SC-NFs to internal neurofibromas at risk for malignant transformation and to axonal neuropathies with slowed conduction velocities. Axonal neuropathies with SCV are particularly common in patients with at least ten SC-NFs.</p> <p>Registration details</p> <p>ORPHA86301</p

Mortality Associated with Neurofibromatosis 1: A Cohort Study of 1895 Patients in 1980-2006 in France

<p>Abstract</p> <p>Background</p> <p>Neurofibromatosis 1 (NF1), a common autosomal dominant disorder, was shown in one study to be associated with a 15-year decrease in life expectancy. However, data on mortality in NF1 are limited. Our aim was to evaluate mortality in a large retrospective cohort of NF1 patients seen in France between 1980 and 2006.</p> <p>Methods</p> <p>Consecutive NF1 patients referred to the National French Referral Center for Neurofibromatoses were included. The standardized mortality ratio (SMR) with its 95% confidence interval (CI) was calculated as the ratio of observed over expected numbers of deaths. We studied factors associated with death and causes of death.</p> <p>Results</p> <p>Between 1980 and 2006, 1895 NF1 patients were seen. Median follow-up was 6.8 years (range, 0.4-20.6). Vital status was available for 1226 (65%) patients, of whom 1159 (94.5%) survived and 67 (5.5%) died. Overall mortality was significantly increased in the NF1 cohort (SMR, 2.02; CI, 1.6-2.6; <it>P </it>< 10^-4). The excess mortality occurred among patients aged 10 to 20 years (SMR, 5.2; CI, 2.6-9.3; <it>P </it>< 10^-4) and 20 to 40 years (SMR, 4.1; 2.8-5.8; <it>P </it>< 10^-4). Significant excess mortality was found in both males and females. In the 10-20 year age group, females had a significant increase in mortality compared to males (SMR, 12.6; CI, 5.7-23.9; and SMR, 1.8; CI, 0.2-6.4; respectively). The cause of death was available for 58 (86.6%) patients; malignant nerve sheath tumor was the main cause of death (60%).</p> <p>Conclusions</p> <p>We found significantly increased SMRs indicating excess mortality in NF1 patients compared to the general population. The definitive diagnosis of NF1 in all patients is a strength of our study, and the high rate of death related to malignant transformation is consistent with previous work. The retrospective design and hospital-based recruitment are limitations of our study. Mortality was significantly increased in NF1 patients aged 10 to 40 years and tended to be higher in females than in males.</p

Enhanced Drug Photosafety by Interchromophoric Interaction Due to Intramolecular Charge Separation

[EN] Imatinib is a synthetic tyrosinase inhibitor that is employed for the treatment of some kinds of human cancer. This drug has a low phototoxicity towards DNA, but its pyridylpyrimidine (1) fragment by itself exhibits significant phototoxicitiy. The intrinsic mechanism that leads to the enhanced photosafety of Imatinib is not yet known. Here, the properties of the excited state and interchromophoric interactions of Imatinib have been explored by using ultrafast laser flash photolysis and agarose electrophoresis studies. An intramolecular charge separation was directly observed for the irradiated Imatinib, which accounts for the relaxation of its excited state. An anionic form of pyridylpyrimidine (1) was deduced from the results of time-resolved resonance Raman spectra and by quenching experimental studies on compound 1 and diaminotoluene. In contrast, compound 1 efficiently transformed into triplet excited states with a long lifetime, which explained the phototoxicity associated with this fragment. This work provides insight into how to design drugs with lower phototoxicitiy or improved photostability by using interchromophoric interactions.This work was supported by Natural Science Foundation of China (21773151) and Shantou University Initial Funding (NTF16010). The Support from the Hong Kong Research Grants Council grants GRF 17307916, AoE/P-03/08, SEG HKU/07, The University of Hong Kong Development Fund 2013-2014 project "New Ultrafast Spectroscopy Experiments for Shared Facilities", the Spanish Government (CTQ2015-70164-P and BES-2013-066566) are also acknowledged.Li, M.; Yan, Z.; Zhu, R.; Phillips, DL.; Aparici-Espert, MI.; Lhiaubet, VL.; Miranda Alonso, MÁ. (2018). Enhanced Drug Photosafety by Interchromophoric Interaction Due to Intramolecular Charge Separation. Chemistry - A European Journal. 24(25):6654-6659. https://doi.org/10.1002/chem.201800716S665466592425Patel, S. (2013). Long-term efficacy of imatinib for treatment of metastatic GIST. Cancer Chemotherapy and Pharmacology, 72(2), 277-286. doi:10.1007/s00280-013-2135-8Lydon, N. (2009). Attacking cancer at its foundation. Nature Medicine, 15(10), 1153-1157. doi:10.1038/nm1009-1153Bucci, M., Goodman, C., & Sheppard, T. L. (2010). A decade of chemical biology. Nature Chemical Biology, 6(12), 847-854. doi:10.1038/nchembio.489Yang, J. C., Niu, D., Karsten, B. P., Lima, F., & Buchwald, S. L. (2016). Use of a «Catalytic» Cosolvent, N ,N -Dimethyl Octanamide, Allows the Flow Synthesis of Imatinib with no Solvent Switch. Angewandte Chemie International Edition, 55(7), 2531-2535. doi:10.1002/anie.201509922Yang, J. C., Niu, D., Karsten, B. P., Lima, F., & Buchwald, S. L. (2016). Use of a «Catalytic» Cosolvent, N ,N -Dimethyl Octanamide, Allows the Flow Synthesis of Imatinib with no Solvent Switch. Angewandte Chemie, 128(7), 2577-2581. doi:10.1002/ange.201509922Ōmura, S. (2016). A Splendid Gift from the Earth: The Origins and Impact of the Avermectins (Nobel Lecture). Angewandte Chemie International Edition, 55(35), 10190-10209. doi:10.1002/anie.201602164Ōmura, S. (2016). Ein vortreffliches Geschenk der Erde: Ursprünge und Auswirkungen der Avermectine (Nobel-Aufsatz). Angewandte Chemie, 128(35), 10344-10364. doi:10.1002/ange.201602164Korch, K. M., Eidamshaus, C., Behenna, D. C., Nam, S., Horne, D., & Stoltz, B. M. (2014). Enantioselective Synthesis of α-Secondary and α-Tertiary Piperazin-2-ones and Piperazines by Catalytic Asymmetric Allylic Alkylation. Angewandte Chemie International Edition, 54(1), 179-183. doi:10.1002/anie.201408609Korch, K. M., Eidamshaus, C., Behenna, D. C., Nam, S., Horne, D., & Stoltz, B. M. (2014). Enantioselective Synthesis of α-Secondary and α-Tertiary Piperazin-2-ones and Piperazines by Catalytic Asymmetric Allylic Alkylation. Angewandte Chemie, 127(1), 181-185. doi:10.1002/ange.201408609Lydon, N. B., & Druker, B. J. (2004). Lessons learned from the development of imatinib. Leukemia Research, 28, 29-38. doi:10.1016/j.leukres.2003.10.002AMITAY-LAISH, I., STEMMER, S. M., & LACOUTURE, M. E. (2011). Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatologic Therapy, 24(4), 386-395. doi:10.1111/j.1529-8019.2011.01431.xRousselot, P., Larghero, J., Raffoux, E., Calvo, F., Tulliez, M., Giraudier, S., & Rybojad, M. (2003). Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. British Journal of Haematology, 120(6), 1091-1092. doi:10.1046/j.1365-2141.2003.04208_3.xBrazzelli, V., Muzio, F., Manna, G., Moggio, E., Vassallo, C., Orlandi, E., … Borroni, G. (2011). Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate. Photodermatology, Photoimmunology & Photomedicine, 28(1), 2-5. doi:10.1111/j.1600-0781.2011.00621.xAtalay, F., Kızılkılıç, E., & Ada, R. S. (2013). Imatinib-Induced Psoriasis. Turkish Journal of Hematology, 30(2), 216-218. doi:10.4274/tjh.2012.0147Valeyrie, L., Bastuji-Garin, S., Revuz, J., Bachot, N., Wechsler, J., Berthaud, P., … Giraudier, S. (2003). Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients. Journal of the American Academy of Dermatology, 48(2), 201-206. doi:10.1067/mjd.2003.44Heidary, N., Naik, H., & Burgin, S. (2008). Chemotherapeutic agents and the skin: An update. Journal of the American Academy of Dermatology, 58(4), 545-570. doi:10.1016/j.jaad.2008.01.001Timmer-de Mik, L., Kardaun, S. H., Kramer, M. H. H., Hayes, D. P., & Bousema, M. T. (2009). Imatinib-induced pseudoporphyria. Clinical and Experimental Dermatology, 34(6), 705-707. doi:10.1111/j.1365-2230.2008.02985.xBaskaynak, G., Kreuzer, K.-A., Schwarz, M., Zuber, J., Audring, H., Riess, H., … Le Coutre, P. (2003). Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. European Journal of Haematology, 70(4), 231-234. doi:10.1034/j.1600-0609.2003.00044.xNardi, G., Lhiaubet-Vallet, V., & Miranda, M. A. (2014). Photosensitization by Imatinib. A Photochemical and Photobiological Study of the Drug and Its Substructures. Chemical Research in Toxicology, 27(11), 1990-1995. doi:10.1021/tx500328qDeria, P., Yu, J., Smith, T., & Balaraman, R. P. (2017). Ground-State versus Excited-State Interchromophoric Interaction: Topology Dependent Excimer Contribution in Metal–Organic Framework Photophysics. Journal of the American Chemical Society, 139(16), 5973-5983. doi:10.1021/jacs.7b02188Liu, B., Zhao, J., Luo, C., Lu, F., Tao, S., & Tong, Q. (2016). A novel bipolar phenanthroimidazole derivative host material for highly efficient green and orange-red phosphorescent OLEDs with low efficiency roll-off at high brightness. Journal of Materials Chemistry C, 4(10), 2003-2010. doi:10.1039/c5tc04393jFang, C., Frontiera, R. R., Tran, R., & Mathies, R. A. (2009). Mapping GFP structure evolution during proton transfer with femtosecond Raman spectroscopy. Nature, 462(7270), 200-204. doi:10.1038/nature08527Nicolaou, K. C. (2014). Advancing the Drug Discovery and Development Process. Angewandte Chemie International Edition, 53(35), 9128-9140. doi:10.1002/anie.201404761Nicolaou, K. C. (2014). Advancing the Drug Discovery and Development Process. Angewandte Chemie, 126(35), 9280-9292. doi:10.1002/ange.201404761Li, M.-D., Hanway, P. J., Albright, T. R., Winter, A. H., & Phillips, D. L. (2014). Direct Spectroscopic Observation of Closed-Shell Singlet, Open-Shell Singlet, and Triplet p-Biphenylyloxenium Ion. Journal of the American Chemical Society, 136(35), 12364-12370. doi:10.1021/ja505447qLi, M.-D., Albright, T. R., Hanway, P. J., Liu, M., Lan, X., Li, S., … Phillips, D. L. (2015). Direct Spectroscopic Detection and EPR Investigation of a Ground State Triplet Phenyl Oxenium Ion. Journal of the American Chemical Society, 137(32), 10391-10398. doi:10.1021/jacs.5b06302Du, L., Qiu, Y., Lan, X., Zhu, R., Phillips, D. L., Li, M.-D., … Winter, A. H. (2017). Direct Detection of the Open-Shell Singlet Phenyloxenium Ion: An Atom-Centered Diradical Reacts as an Electrophile. Journal of the American Chemical Society, 139(42), 15054-15059. doi:10.1021/jacs.7b07512Li, M.-D., Ma, J., Su, T., Liu, M., Yu, L., & Phillips, D. L. (2012). Direct Observation of Triplet State Mediated Decarboxylation of the Neutral and Anion Forms of Ketoprofen in Water-Rich, Acidic, and PBS Solutions. The Journal of Physical Chemistry B, 116(20), 5882-5887. doi:10.1021/jp301555eO’boyle, N. M., Tenderholt, A. L., & Langner, K. M. (2008). cclib: A library for package-independent computational chemistry algorithms. Journal of Computational Chemistry, 29(5), 839-845. doi:10.1002/jcc.20823Merrick, J. P., Moran, D., & Radom, L. (2007). An Evaluation of Harmonic Vibrational Frequency Scale Factors. The Journal of Physical Chemistry A, 111(45), 11683-11700. doi:10.1021/jp073974

Toxic epidermal necrolysis and Stevens-Johnson syndrome

Toxic epidermal necrolysis (TEN) and Stevens Johnson Syndrome (SJS) are severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes. Both are rare, with TEN and SJS affecting approximately 1or 2/1,000,000 annually, and are considered medical emergencies as they are potentially fatal. They are characterized by mucocutaneous tenderness and typically hemorrhagic erosions, erythema and more or less severe epidermal detachment presenting as blisters and areas of denuded skin. Currently, TEN and SJS are considered to be two ends of a spectrum of severe epidermolytic adverse cutaneous drug reactions, differing only by their extent of skin detachment. Drugs are assumed or identified as the main cause of SJS/TEN in most cases, but Mycoplasma pneumoniae and Herpes simplex virus infections are well documented causes alongside rare cases in which the aetiology remains unknown. Several drugs are at "high" risk of inducing TEN/SJS including: Allopurinol, Trimethoprim-sulfamethoxazole and other sulfonamide-antibiotics, aminopenicillins, cephalosporins, quinolones, carbamazepine, phenytoin, phenobarbital and NSAID's of the oxicam-type. Genetic susceptibility to SJS and TEN is likely as exemplified by the strong association observed in Han Chinese between a genetic marker, the human leukocyte antigen HLA-B*1502, and SJS induced by carbamazepine. Diagnosis relies mainly on clinical signs together with the histological analysis of a skin biopsy showing typical full-thickness epidermal necrolysis due to extensive keratinocyte apoptosis. Differential diagnosis includes linear IgA dermatosis and paraneoplastic pemphigus, pemphigus vulgaris and bullous pemphigoid, acute generalized exanthematous pustulosis (AGEP), disseminated fixed bullous drug eruption and staphyloccocal scalded skin syndrome (SSSS). Due to the high risk of mortality, management of patients with SJS/TEN requires rapid diagnosis, evaluation of the prognosis using SCORTEN, identification and interruption of the culprit drug, specialized supportive care ideally in an intensive care unit, and consideration of immunomodulating agents such as high-dose intravenous immunoglobulin therapy. SJS and TEN are severe and life-threatening. The average reported mortality rate of SJS is 1-5%, and of TEN is 25-35%; it can be even higher in elderly patients and those with a large surface area of epidermal detachment. More than 50% of patients surviving TEN suffer from long-term sequelae of the disease

AP1S3 Mutations Cause Skin Autoinflammation by Disrupting Keratinocyte Autophagy and Up-Regulating IL-36 Production

Prominent skin involvement is a defining characteristic of autoinflammatory disorders caused by abnormal IL-1 signaling. However, the pathways and cell types that drive cutaneous autoinflammatory features remain poorly understood. We sought to address this issue by investigating the pathogenesis of pustular psoriasis, a model of autoinflammatory disorders with predominant cutaneous manifestations. We specifically characterized the impact of mutations affecting AP1S3, a disease gene previously identified by our group and validated here in a newly ascertained patient resource. We first showed that AP1S3 expression is distinctively elevated in keratinocytes. Because AP1S3 encodes a protein implicated in autophagosome formation, we next investigated the effects of gene silencing on this pathway. We found that AP1S3 knockout disrupts keratinocyte autophagy, causing abnormal accumulation of p62, an adaptor protein mediating NF-kappa B activation. We showed that as a consequence, AP1S3-deficient cells up-regulate IL-1 signaling and overexpress IL-36 alpha, a cytokine that is emerging as an important mediator of skin inflammation. These abnormal immune profiles were recapitulated by pharmacological inhibition of autophagy and verified in patient keratinocytes, where they were reversed by IL-36 blockade. These findings show that keratinocytes play a key role in skin autoinflammation and identify autophagy modulation of IL-36 signaling as a therapeutic target.Peer reviewe